Mannitol

Mannitol

SCHEMBL5565935

OCC(O)CO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.79
L3MBTL1 Q9Y468 1/20 0.79
TDP1 Q9NUW8 2/20 0.73
ALDH1A1 P00352 2/20 0.64
KDM4E B2RXH2 2/20 0.50
PDE4A P27815 1/20 0.50
USP2 O75604 1/20 0.46
SLCO1B1 Q9Y6L6 1/20 0.46
THRB P10828 1/20 0.42
MAPT P10636 1/20 0.35
TOP1 P11387 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sorbitol SCHEMBL11519008 1.00 LMNA (0.79) LMNAL3MBTL1TDP1ALDH1A1KDM4E
Mannitol SCHEMBL8671937 1.00 LMNA (0.79) LMNAL3MBTL1TDP1ALDH1A1KDM4E
Galactitol SCHEMBL11516787 1.00 LMNA (0.79) LMNAL3MBTL1TDP1ALDH1A1KDM4E
Mannitol SCHEMBL27259380 1.00 LMNA (0.79) LMNAL3MBTL1TDP1ALDH1A1KDM4E
Sorbitol SCHEMBL232913 1.00 LMNA (0.79) LMNAL3MBTL1TDP1ALDH1A1KDM4E
Sorbitol SCHEMBL9654601 1.00 LMNA (0.79) LMNAL3MBTL1TDP1ALDH1A1KDM4E
Mannitol SCHEMBL28980943 1.00 LMNA (0.79) LMNAL3MBTL1TDP1ALDH1A1KDM4E
Sorbitol SCHEMBL8145945 0.97 LMNA (0.73) LMNAL3MBTL1TDP1ALDH1A1KDM4E
Mannitol SCHEMBL2785381 0.94 LMNA (0.69) LMNAL3MBTL1TDP1ALDH1A1KDM4E
Mannitol SCHEMBL9580709 0.94 LMNA (0.69) LMNAL3MBTL1TDP1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117414735-A Collagen composite product production equipment and process thereof 河南健帝宠物营养科技发展有限公司 2024-01-19 CN claimed
EP-3197952-B1 BIODEGRADABLE POLYMER RECYCLING JOHNSON ANTHONY FRANCIS (GB) 2023-10-18 EP claimed
CN-110255615-A A method of using arsenic alkaline slag as waste antimony oxide, arsenate and soda ash 长沙紫宸科技开发有限公司 2019-09-20 CN claimed
US-20170233543-A1 BIODEGRADABLE POLYMER RECYCLING AQUAPAK IP LTD (GB) 2017-08-17 US claimed
EP-3197952-A1 BIODEGRADABLE POLYMER RECYCLING Johnson, Anthony Francis (GB) 2017-08-02 EP claimed
WO-2016046520-A1 BIODEGRADABLE POLYMER RECYCLING JOHNSON ANTHONY FRANCIS (GB) 2016-03-31 WO claimed
CN-104127464-A Ophthalmic Blumea balsamifera oil preparation and preparation method thereof UNIV GUIZHOU 2014-11-05 CN claimed
US-20070087939-A1 Biopolymer compositions and products thereof PFIZER INC. 2007-04-19 US claimed
EP-1735377-A1 BIOPOLYMER COMPOSITIONS AND PRODUCTS THEREOF Warner-Lambert Company LLC (US) 2006-12-27 EP claimed
WO-2005092968-A1 BIOPOLYMER COMPOSITIONS AND PRODUCTS THEREOF WARNER-LAMBERT COMPANY LLC (US) 2005-10-06 WO claimed
EP-1580229-A1 Biopolymer compositons and products thereof WARNER-LAMBERT COMPANY LLC (US) 2005-09-28 EP claimed
WO-2001072684-B1 PROCESS FOR THE PREPARATION OF POLYMORPH OF 4-(ARYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE DERIVATIVE SUN PHARMACEUTICAL IND LTD (IN) 2001-11-29 WO claimed
US-5698219-A CONTAINING NONIONIC SURFACTANT LABORATORIOS CUSI, S.A. (ES) 1997-12-16 US claimed
CN-117414735-A Collagen composite product production equipment and process thereof 河南健帝宠物营养科技发展有限公司 2024-01-19 CN disclosed
EP-3197952-B1 BIODEGRADABLE POLYMER RECYCLING JOHNSON ANTHONY FRANCIS (GB) 2023-10-18 EP disclosed
US-20220000772-A1 SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS AVALYN PHARMA INC. 2022-01-06 US disclosed
EP-0369474-A2 Pharmaceutical composition for the treatment of cerebral edema Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1990-05-23 EP disclosed
EP-0211506-A1 Heteropolysaccharide and its Production and use MERCK & CO. INC. (US) 1987-02-25 EP disclosed
US-4283492-A STREPTOMYCES CULTURE PRODUCT FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-08-11 US disclosed
US-4108807-A REACTING A METALLATE WITH A PSEUDOHALIDE IN THE PRESENCE OF A PHENOL-SUBSTITUTED TERTIARY AMINE CATALYST CHEMIC-ANLAGENBAU BISCHOFSHEIM GMBH (DE) 1978-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000772-A1 SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS FGF2, FIBP, REN LMNA 3273/4885L3MBTL1 3670/4885TDP1 4195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.